<DOC>
	<DOCNO>NCT00975130</DOCNO>
	<brief_summary>Part 1 trial ass safety effectiveness subcutaneous ( SC ) golimumab administer autoinjector monthly , combine different disease-modifying antirheumatic drug ( DMARD ) regimens used daily rheumatology practice . Subsequently , Part 2 study strategy intravenous ( IV ) golimumab induce remission follow SC golimumab retain remission superior continue SC regimen .</brief_summary>
	<brief_title>Subcutaneous Golimumab ( GLM ) Plus DMARDs Rheumatoid Arthritis , Followed Intravenous/Subcutaneous GLM Strategy ( P06129 AM2 )</brief_title>
	<detailed_description>Participants good moderate European League Against Rheumatism ( EULAR ) response achieve remission end Part 1 invite participate Part 2 randomize either intravenous golimumab ( IV GLM ) + subcutaneous golimumab ( SC GLM ) SC GLM alone .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>For Part 1 : Age &gt; =18 year , either sex , race . Diagnosis RA accord 1987 revised American College Rheumatology ( ACR ) criterion . Active disease despite DMARD treatment Subject must take least one allow DMARDs , must able continue trial . Eligibility anti tumor necrosis factor ( TNF ) use accord follow criterion : Participant must fail conventional treatment accord investigator 's opinion OR local guideline . Local guideline regard safety screen anti TNF candidate ( ie , tuberculosis [ TB ] screen safety screen vaccination , applicable ) must meet . Chest Xray either PPD skin test QuantiFERONÂ®TB Gold test also require . Anamnesis physical examination must make participant eligible anti TNF use trial participation accord investigator 's judgment . For Part 2 : Participant must complete Part 1 trial . Participant must : good moderate response SC golimumab end Month 6 compare Baseline , AND . DAS28 ESR remission . Both investigator subject must agree switch participant 's treatment IV administration may require Part 2 trial . The investigator must judge safety event ( eg , serious adverse event [ SAEs ] , serious infection , mark injectionsite reaction intolerance drug ) occur could reoccur aggravate increase drug exposure . History biologic drug use RA . Evidence active TB . latent TB untreated . Moderate severe heart failure Certain inflammatory rheumatic disease RA certain systemic inflammatory condition Allergy latex</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>